September 27, 2016 6:46 PM ET

Biotechnology

Company Overview of Five Prime Therapeutics, Inc.

Company Overview

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast grow...

Two Corporate Drive

South San Francisco, CA 94080

United States

Founded in 2001

154 Employees

Phone:

415-365-5600

Fax:

415-365-5601

Key Executives for Five Prime Therapeutics, Inc.

Founder, Chairman, Chief Executive Officer and President
Age: 67
Total Annual Compensation: $525.0K
Chief Operating Officer and Director
Age: 47
Total Annual Compensation: $383.5K
Chief Strategy Officer and Secretary
Age: 45
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.

Five Prime Therapeutics, Inc. Key Developments

Five Prime Therapeutics, Inc. Promotes Aron M. Knickerbocker to the Position of Chief Operating Officer and its Principal Operating Officer

On September 8, 2016, the Board of Directors of Five Prime Therapeutics, Inc. promoted Aron M. Knickerbocker, FivePrime's previous Chief Business Officer, to the position of Chief Operating Officer and appointed Mr. Knickerbocker as FivePrime's principal operating officer, effective immediately.

Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM

Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.

Five Prime Therapeutics, Inc. Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Net Cash Used in Operating Activities Guidance for the Full Year 2016

Five Prime Therapeutics, Inc. reported financial results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported collaboration revenue was $9,229,000 against $6,315,000 a year ago. Loss from operations was $21,054,000 against $11,591,000 a year ago. Loss before income tax was $20,408,000 against $11,474,000 a year ago. Net loss was $13,137,000 against $11,474,000 a year ago. Basic and diluted net loss per common share was $0.49 against $0.45 a year ago. For the six months, the company reported collaboration revenue was $15,749,000 against $10,602,000 a year ago. Loss from operations was $41,447,000 against $22,735,000 a year ago. Loss before income tax was $40,265,000 against $22,510,000 a year ago. Net loss was $26,117,000 against $22,510,000 a year ago. Basic and diluted net loss per common share was $0.98 against $0.89 a year ago. The company continues to expect full-year 2016 net cash used in operating activities to be less than $120 million, comprising less than $90 million used in operations and less than $30 million used for tax payments.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Five Prime Therapeutics, Inc., please visit www.fiveprime.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.